Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Revenue
Royalty and licensing revenue	$ 0	$ 2,605,097	$ 14,656,142	$ 4,785,097
Treatment investment revenue	18,116	0	18,116	4,800,000
Total revenue	18,116	2,605,097	14,674,258	9,585,097
Operating expenses
General and administrative	1,995,892	1,040,608	4,567,898	13,155,931
Research and development	1,103,319	1,059,627	1,889,989	2,814,520
Selling expenses	84,375	93,000	1,322,974	302,251
Total operating expenses	3,183,586	2,193,235	7,780,861	16,272,702
Income (loss) from operations	(3,165,470)	411,862	6,893,397	(6,687,605)
Other income (expense)
Interest income (expense), net	10,673	0	9,306	(11,319)
Income (loss) on foreign exchange	25,189	4,266	16,851	(24,925)
Total other income (expense)	35,862	4,266	26,157	(36,244)
Income (loss) before provision for income taxes	(3,129,608)	416,128	6,919,554	(6,723,849)
Provision for income taxes	0	0	0	0
Net income (loss)	$ (3,129,608)	$ 416,128	$ 6,919,554	$ (6,723,849)
Basic income (loss) per common share	$ (1.55)	$ 0.22	$ 3.45	$ (3.57)
Diluted income (loss) per common share	$ (1.55)	$ 0.15	$ 3.07	$ (3.57)
Basic weighted average common shares outstanding	2,014,141	1,916,554	2,004,143	1,882,088
Diluted weighted average common shares outstanding	2,014,141	2,734,760	2,251,127	1,882,088